CRISM Therapeutics Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRTX.L research report →
Companywww.crismtherapeutics.com
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor.
- CEO
- Andrew Webb
- IPO
- 2003
- Employees
- 4
- HQ
- Road Town, VG
Price Chart
Valuation
- Market Cap
- $4.50M
- P/E
- -4.08
- P/S
- 0.00
- P/B
- 2.90
- EV/EBITDA
- -4.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.00%
- ROIC
- -69.31%
Growth & Income
- Revenue
- $25.00K · -56.42%
- Net Income
- $-607,000 · 93.71%
- EPS
- $-0.10 · -46.55%
- Op Income
- $-582,000
- FCF YoY
- 65.31%
Performance & Tape
- 52W High
- $25.00
- 52W Low
- $8.00
- 50D MA
- $12.14
- 200D MA
- $11.41
- Beta
- 0.61
- Avg Volume
- 212.62K
Get TickerSpark's AI analysis on CRTX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CRTX.L Coverage
We haven't published any research on CRTX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRTX.L Report →